Acromegaly Completed Phase 3 Trials for Lanreotide (DB06791)

Back to Acromegaly

Also known as: Acromegalic / Acromegaly (disorder)

IndicationStatusPhase
DBCOND0000951 (Acromegaly)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02493517
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in AcromegalyTreatment
NCT01137682
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled AcromegalyTreatment
NCT00690898
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaTreatment
NCT00499993
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyTreatment
NCT00447499
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelTreatment
NCT00444873
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyTreatment
NCT00383708
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsTreatment
NCT00210457
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsTreatment